DE69918072D1 - P53-regulierte gene - Google Patents

P53-regulierte gene

Info

Publication number
DE69918072D1
DE69918072D1 DE69918072T DE69918072T DE69918072D1 DE 69918072 D1 DE69918072 D1 DE 69918072D1 DE 69918072 T DE69918072 T DE 69918072T DE 69918072 T DE69918072 T DE 69918072T DE 69918072 D1 DE69918072 D1 DE 69918072D1
Authority
DE
Germany
Prior art keywords
genes
expression
regulated
bypassed
defects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918072T
Other languages
English (en)
Other versions
DE69918072T2 (de
Inventor
J Levine
E Murphy
H Mack
C Gish
Yat Tom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymetrix Inc
Princeton University
Original Assignee
Affymetrix Inc
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymetrix Inc, Princeton University filed Critical Affymetrix Inc
Application granted granted Critical
Publication of DE69918072D1 publication Critical patent/DE69918072D1/de
Publication of DE69918072T2 publication Critical patent/DE69918072T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
DE69918072T 1998-03-27 1999-03-26 P53-regulierte gene Expired - Lifetime DE69918072T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49025 1998-03-27
US09/049,025 US6020135A (en) 1998-03-27 1998-03-27 P53-regulated genes
PCT/US1999/006656 WO1999050456A1 (en) 1998-03-27 1999-03-26 P53-regulated genes

Publications (2)

Publication Number Publication Date
DE69918072D1 true DE69918072D1 (de) 2004-07-22
DE69918072T2 DE69918072T2 (de) 2005-07-07

Family

ID=21957674

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918072T Expired - Lifetime DE69918072T2 (de) 1998-03-27 1999-03-26 P53-regulierte gene

Country Status (8)

Country Link
US (3) US6020135A (de)
EP (1) EP1064404B1 (de)
JP (1) JP2002509732A (de)
AT (1) ATE269415T1 (de)
AU (1) AU3208599A (de)
CA (1) CA2324444A1 (de)
DE (1) DE69918072T2 (de)
WO (1) WO1999050456A1 (de)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6355430B1 (en) * 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6936424B1 (en) 1999-11-16 2005-08-30 Matritech, Inc. Materials and methods for detection and treatment of breast cancer
WO2001062965A2 (en) * 2000-02-22 2001-08-30 Oxford Biomedica (Uk) Limited Differential expression screening method
US6884578B2 (en) 2000-03-31 2005-04-26 Affymetrix, Inc. Genes differentially expressed in secretory versus proliferative endometrium
WO2001083740A2 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1297186A4 (de) * 2000-06-30 2005-06-29 Univ Utah Res Found Methode zum durchmustern für chemotherapeutische krebstherapien
US7567870B1 (en) * 2000-07-31 2009-07-28 Institute For Systems Biology Multiparameter analysis for predictive medicine
DE10037769A1 (de) * 2000-08-03 2002-02-21 Epigenomics Gmbh Diagnose von mit CD24 assoziierten Krankheiten
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US6713257B2 (en) * 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US7108969B1 (en) * 2000-09-08 2006-09-19 Affymetrix, Inc. Methods for detecting and diagnosing oral cancer
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
DE10048633A1 (de) * 2000-09-25 2002-04-18 Schering Ag Methode zur in vitro Diagnostik von Endometriose
US6403372B1 (en) 2000-11-27 2002-06-11 Cytokinetics, Inc. Aspergillus fumigatus profilin
US6743897B1 (en) 2000-11-27 2004-06-01 Cytokinetics, Inc. Aspergillus fumigatus profilin
ATE483976T1 (de) * 2001-06-05 2010-10-15 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
SG143977A1 (en) * 2001-06-05 2008-07-29 Auckland Uniservices Ltd Methods and compositions for assessment of pulmonary function and disorders
US7981842B2 (en) 2001-06-08 2011-07-19 Panomics, Inc. Method for detecting transcription factor-protein interactions
US20040214166A1 (en) * 2001-06-08 2004-10-28 Xianqiang Li Method for identifying a disease state based on a detected mixture of activated transcription factors
US6696256B1 (en) 2001-06-08 2004-02-24 Pandmics, Inc. Method, array and kit for detecting activated transcription factors by hybridization array
US6924113B2 (en) 2001-06-08 2005-08-02 Panomics, Inc. Method and kit for isolating DNA probes that bind to activated transcription factors
US6821737B2 (en) 2001-06-08 2004-11-23 Panomics, Inc. Method for screening for drug candidates for modulating transcription factor activity
US7343247B2 (en) * 2001-07-30 2008-03-11 The Institute For Systems Biology Methods of classifying drug responsiveness using multiparameter analysis
EP1434863A4 (de) * 2001-08-29 2006-03-08 Univ Illinois IDENTIFIZIERUNG UND VERWENDUNG VON p21-INHIBITOREN AUS SÄUGERN
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
WO2003053586A1 (en) * 2001-12-19 2003-07-03 Affymetrix, Inc. Array plates and method for constructing array plates
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
US20040096874A1 (en) * 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
AU2003259795A1 (en) * 2002-08-19 2004-03-03 Yun Yen Treatment of liver deseases
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP1633892A4 (de) 2003-06-10 2007-10-24 Univ Boston Nachweismethoden für lungenerkrankungen
EP3170906B1 (de) 2003-06-24 2018-08-22 Genomic Health, Inc. Vorhersage der wahrscheinlichkeit eines wiederauftretens von krebs
EP3330875B1 (de) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expressionsprofilalgorithmus und -test zur prognose des wiederauftretens von brustkrebs
SG146682A1 (en) 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
CA2551267C (en) * 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
CA2497324A1 (en) 2004-02-17 2005-08-17 Affymetrix, Inc. Methods for fragmenting and labelling dna
KR20080075045A (ko) 2004-03-24 2008-08-13 트리패스 이미징, 인코포레이티드 자궁경부 질환의 검사 방법 및 조성물
US7871769B2 (en) * 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20060073506A1 (en) 2004-09-17 2006-04-06 Affymetrix, Inc. Methods for identifying biological samples
US20060068434A1 (en) * 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
EP1645640B1 (de) 2004-10-05 2013-08-21 Affymetrix, Inc. Verfahren zur Detektion von chromosomalen Translokationen
EP2302388A1 (de) * 2004-10-14 2011-03-30 Genentech, Inc. COP1-Moleküle und deren Verwendungen
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
CA2524964A1 (en) 2004-10-29 2006-04-29 Affymetrix, Inc. Automated method of manufacturing polymer arrays
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2585561C (en) * 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
EP2360278A1 (de) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnose für Lungenerkrankungen mittels Klassenvorhersage
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
US20060269946A1 (en) * 2005-05-10 2006-11-30 Young Robert P Methods and compositions for assessment of pulmonary function and disorders
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
JP2008545389A (ja) * 2005-05-19 2008-12-18 シナージェンズ バイオサイエンス リミティド 肺機能及び肺障害の評価のための方法及び組成物
AU2006248201A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
EP1888779A4 (de) * 2005-05-20 2009-06-10 Synergenz Bioscience Ltd Verfahren zur analyse von polymorphismen sowie verwendungen davon
CA2616138A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of monitoring the operation of a medical device
WO2007014093A2 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for processing data relating to a radiation therapy treatment plan
JP2009502255A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 治療プランのデリバリにおける品質保証基準を評価するための方法およびシステム
CA2616316A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for adapting a radiation therapy treatment plan based on a biological model
AU2006272742A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
US7609809B2 (en) 2005-07-22 2009-10-27 Tomo Therapy Incorporated System and method of generating contour structures using a dose volume histogram
JP2009502257A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド デリバーされた線量を評価するための方法およびシステム
KR20080039916A (ko) * 2005-07-22 2008-05-07 토모테라피 인코포레이티드 움직이는 관심 영역에 방사선 치료를 시행하는 시스템 및방법
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
US7839972B2 (en) * 2005-07-22 2010-11-23 Tomotherapy Incorporated System and method of evaluating dose delivered by a radiation therapy system
EP1907058B1 (de) * 2005-07-22 2015-06-24 TomoTherapy, Inc. Verfahren zur positionierung von beschränkungen auf einer deformationsabbildung und system zur umsetzung
CA2616309A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method of and system for predicting dose delivery
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
JP2009506778A (ja) * 2005-09-02 2009-02-19 ザ・ユニバーシティ・オブ・トレド 生物学的状態の診断および／または治療に有用なバイオマーカを同定する方法および組成物
EP1941057A4 (de) * 2005-10-07 2009-11-11 Baylor Res Inst Diagnose des systemischen ausbruchs juveniler idiopathischer arthritis über blutleukozyten-mikroarrayanalyse
US7634363B2 (en) * 2005-12-07 2009-12-15 Affymetrix, Inc. Methods for high throughput genotyping
US7846664B2 (en) * 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
WO2007069882A1 (en) * 2005-12-13 2007-06-21 Erasmus University Medical Center Rotterdam Genetic brain tumor markers
EP1987360B1 (de) 2006-01-27 2012-03-07 Tripath Imaging, Inc. Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür
EP1999472A2 (de) 2006-03-09 2008-12-10 The Trustees Of Boston University Diagnose- und prognoseverfahren für lungenerkrankungen mittels genexpressionsprofilen aus nasenepithelzellen
CN101437536A (zh) 2006-03-23 2009-05-20 诺华有限公司 抗肿瘤细胞抗原抗体治疗
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008024114A1 (en) * 2006-08-24 2008-02-28 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia
US20100267575A1 (en) * 2006-10-17 2010-10-21 Childrens Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
EP2570951A1 (de) 2006-11-03 2013-03-20 Baylor Research Institute Diagnose eines metastatischen Melanoms und Überwachung der Immunosuppressionsindikatoren durch Blutleukozyten-Mikroarray-Analyse
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
CN101918597B (zh) 2008-03-11 2013-09-18 国立癌中心 应用snp阵列测量染色体、基因或特定核苷酸序列拷贝数的方法
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
AU2009262894B2 (en) 2008-05-30 2014-01-30 British Columbia Cancer Agency Branch Gene expression profiles to predict breast cancer outcomes
EP2408905B1 (de) 2009-03-16 2017-05-10 Pangu Biopharma Limited Zusammensetzungen und verfahren mit histidyl-trna-synthetase-spleissvarianten mit nicht-kanonischen biologischen aktivitäten
AU2010236913B2 (en) 2009-03-31 2016-03-24 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities
DK2488873T3 (en) 2009-10-16 2015-11-09 Novartis Ag Biomarkers for pharmacodynamic tumor responses
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
CN102713632B (zh) 2009-12-23 2015-10-07 希尔氏宠物营养品公司 用于诊断和治疗犬肾脏病症的组合物和方法
AU2011214465A1 (en) 2010-02-10 2012-08-30 Novartis Ag Methods and compounds for muscle growth
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096914B (zh) 2010-05-17 2015-08-12 Atyr医药公司 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
CA2801107A1 (en) 2010-06-07 2011-12-15 F. Hoffman-La Roche Ag Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
EP2603227B1 (de) 2010-08-12 2017-10-04 Fate Therapeutics, Inc. Verbesserte hämatopoetische stamm- und vorläuferzelltherapie
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2012068170A2 (en) 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
CA2819378A1 (en) 2010-12-02 2012-06-07 Katholieke Universiteit Leuven, K.U.Leuven R&D Irak-related interventions and diagnosis
EP2678687B1 (de) 2011-02-24 2015-09-02 Hill's Pet Nutrition, Inc. Zusammensetzungen und verfahren zur diagnostizierung und behandlung von nierenerkrankungen bei katzen
EP2680839A1 (de) 2011-03-02 2014-01-08 Morphotek, Inc. Gleichzeitige verabreichung von eribulin und farletuzumab zur behandlung von brustkrebs
PH12013501802B1 (en) 2011-03-02 2018-06-27 Berg Llc Interrogatory cell-based assays and uses thereof
US9066963B2 (en) 2011-03-15 2015-06-30 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with anthracycline therapy
WO2012129100A1 (en) 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
CA2839207A1 (en) 2011-06-15 2012-12-20 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
US20140017174A1 (en) 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
RU2612901C2 (ru) 2011-12-19 2017-03-13 Хилл'С Пет Ньютришн, Инк. Композиции и способы диагностики и лечения гипертиреоза у животных-компаньонов
IN2014MN01642A (de) 2012-02-16 2015-07-03 Atyr Pharma Inc
US11177020B2 (en) 2012-02-27 2021-11-16 The University Of North Carolina At Chapel Hill Methods and uses for molecular tags
CA2865575C (en) 2012-02-27 2024-01-16 Cellular Research, Inc. Compositions and kits for molecular counting
AU2012376214B2 (en) 2012-04-02 2019-02-14 Berg Llc Interrogatory cell-based assays and uses thereof
CA2869313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Gene expression panel for breast cancer prognosis
CA2874492C (en) 2012-05-22 2021-10-19 British Columbia Cancer Agency Branch Nano46 genes and methods to predict breast cancer outcome
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
MX367366B (es) 2012-11-27 2019-08-16 Univ Pontificia Catolica Chile Composiciones y metodos para diagnosticar tumores de tiroides.
GB2523696B (en) 2012-11-30 2017-12-27 Accelerated Biosciences Corp Methods of differentiating stem cells to pancreatic progenitor cells by modulating miR-124
CN105190314A (zh) 2013-01-21 2015-12-23 阿布维公司 用于炎性疾病的抗-tnf和抗-il17联合疗法生物标志物
WO2014133849A2 (en) 2013-02-26 2014-09-04 Accuray Incorporated Electromagnetically actuated multi-leaf collimator
HK1218576A1 (zh) 2013-02-28 2017-02-24 Caprion Proteomics Inc. 结核病生物标志物及其用途
JP2016537010A (ja) 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ 予後を予測するための方法及びキット、並びに、放射線照射療法を用いた乳癌の治療方法及びキット
EP3052121B1 (de) 2013-10-02 2023-02-22 The Board of Trustees of the Leland Stanford Junior University Wnt-zusammensetzungen und verfahren zur reinigung
EP3110973B1 (de) 2014-02-27 2019-02-06 Katholieke Universiteit Leuven Oxidativer stress und kardiovaskuläre ereignisse
US10704097B2 (en) 2014-02-27 2020-07-07 Katholieke Universiteit Leuven Oxidative stress and cardiovascular disease events
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
CN107208131A (zh) 2014-05-30 2017-09-26 基因中心治疗公司 用于肺癌分型的方法
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
ES2833543T3 (es) 2014-10-24 2021-06-15 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de TGF usando modelos matemáticos de la expresión de genes diana
JP7065610B6 (ja) 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
ES2857953T3 (es) 2014-10-24 2021-09-29 Koninklijke Philips Nv Pronóstico médico y predicción de la respuesta al tratamiento usando las actividades de múltiples rutas de señalización celular
SG11201704291QA (en) 2014-11-26 2017-06-29 Accelerated Biosciences Corp Induced hepatocytes and uses thereof
RU2017120330A (ru) 2014-12-12 2019-01-14 Медивэйшн Простейт Терапьютикс, Ллс Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
WO2016094970A1 (en) 2014-12-19 2016-06-23 Vrije Universiteit Brussel In vitro maturation of a mammalian cumulus oocyte complex
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
US10066229B2 (en) 2015-07-28 2018-09-04 Otonomy, Inc. Treatment using truncated Trk B and Trk C antagonists
US11450409B2 (en) 2015-08-14 2022-09-20 Innosign B.V. Determination of NFkB pathway activity using unique combination of target genes
RU2706203C1 (ru) 2015-10-18 2019-11-14 Эффиметрикс, Инк. Мультиаллельное генотипирование однонуклеотидных полиморфизмов и индел-мутаций
KR20170076480A (ko) 2015-12-24 2017-07-04 삼성전자주식회사 Pint 유전자의 발현 저해제 또는 pint의 활성 저해제를 포함하는 조성물 및 그의 용도
WO2017176652A2 (en) 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
CN109863251B (zh) 2016-05-17 2022-11-18 基因中心治疗公司 对肺鳞状细胞癌亚型分型的方法
EP3458612B1 (de) 2016-05-17 2023-11-15 Genecentric Therapeutics, Inc. Verfahren zur subtypisierung von lungenadenokarzinomen
EP3260552A1 (de) 2016-06-20 2017-12-27 Istituto Europeo di Oncologia (IEO) Verfahren und kits mit gensignaturen zur stratifizierung von brustkrebspatienten
WO2018013883A1 (en) 2016-07-14 2018-01-18 Caprion Proteomics Inc. Biomarkers of latent tuberculosis infection
EP3487874A1 (de) 2016-07-20 2019-05-29 Westfälische Wilhelms-Universität Münster Komplexspezifische standardisierung von immunologischen verfahren zur quantifizierung von s100a12
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Methods of treating glioblastoma
WO2018237344A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. METHODS OF PATIENT SELECTION AND TREATMENT OF CANCERS OVEREXPRESSING TRXR OR PRDX
WO2019018764A1 (en) 2017-07-21 2019-01-24 Genecentric Therapeutics, Inc. METHODS OF DETERMINING RESPONSE TO PARP INHIBITORS
EP3665199A4 (de) 2017-08-07 2021-08-11 Genecentric Therapeutics, Inc. Verfahren zur subtypisierung von plattenepithelkarzinomen an kopf und hals
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF
EP3461916A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der zellulären jak-stat3-signalisierungspfadaktivität mittels mathematischer modellierung der zielgenexpression
EP3461915A1 (de) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären jak-stat1/2-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
EP3502279A1 (de) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Beurteilung der aktivität von zellulären mapk-ap 1-signalisierungspfaden mittels mathematischer modellierung der zielgenexpression
EP3752640A4 (de) 2018-02-13 2021-11-24 Genecentric Therapeutics, Inc. Verfahren zur subtypisierung von blasenkrebs
EP3752604B1 (de) 2018-03-16 2023-10-04 Gopath Laboratories LLC Verfahren zur personalisierten detektion des wiederauftretens von krebs oder metastasen und/oder auswertung des ansprechens auf eine behandlung
US20190366292A1 (en) 2018-05-29 2019-12-05 Centrillion Technologies, Inc. Increasing Efficiency Of Photochemical Reactions On Substrates
CA3111045A1 (en) 2018-09-05 2020-03-12 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft A method for engineering synthetic cis-regulatory dna
CA3115922A1 (en) 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
WO2020104482A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma
BR112021012138A2 (pt) 2018-12-20 2021-08-31 Auransa Inc. Análogos de pentamidina e seus usos
EP3908668A4 (de) 2019-01-11 2022-11-09 University of Virginia Patent Foundation Zusammensetzungen und verfahren zur vorhersage der abnahme der lungenfunktion bei idiopathischer lungenfibrose
EP4121534A1 (de) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
CN115916180A (zh) 2020-03-26 2023-04-04 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物
EP3907301A1 (de) 2020-05-08 2021-11-10 Istituto Europeo di Oncologia S.r.l. Methoden und kits zur bestimmung des risikos eines erneuten auftretens von brustkrebs
EP4453261A1 (de) 2021-12-22 2024-10-30 Cornell University Prognostische/prädiktive epigenetische brustkrebssignatur

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810400D0 (en) * 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
EP0390323B2 (de) * 1989-03-29 2012-08-08 Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
US5936079A (en) * 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
CA2118015A1 (en) * 1992-04-14 1993-10-28 Jeffrey R. Marks Method of detecting tumors containing complexes of p53 and hsp70
WO1994011533A1 (en) * 1992-11-12 1994-05-26 The Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR DETERMINING THE PRESENCE OF FUNCTIONAL p53 IN MAMMALIAN CELLS
DK0931830T3 (da) * 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
WO1995014777A1 (en) * 1993-11-22 1995-06-01 Onyx Pharmaceuticals p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5667987A (en) * 1994-07-12 1997-09-16 Bristol-Myers Squibb Company P53 response genes
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US5702908A (en) * 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
CA2232000A1 (en) * 1995-09-14 1997-03-20 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
AU7127296A (en) * 1995-09-18 1997-04-09 Novartis Ag Assay for identifying inhibitors of the interaction between proteins p53 and dm2
AU8382998A (en) * 1997-07-02 1999-01-25 Genzyme Corporation P53 influenced gene expression
WO1999001763A2 (en) * 1997-07-02 1999-01-14 Board Of Regents, The University Of Texas System p53 AS A REGULATOR OF CELL DIFFERENTIATION
DE19735221C1 (de) * 1997-08-14 1999-05-06 Wolfgang Willi Prof Dr Deppert Beeinflussung der Bindung von p53 an Zielgene
US6432640B1 (en) * 1997-09-17 2002-08-13 The Johns Hopkins University P53-induced apoptosis
US6297366B1 (en) * 1998-01-14 2001-10-02 Board Of Trustees Of The University Of Illinois ING-encoded p33ING1 protein as a mediator of p53 signaling pathway in mammalian cells
AU9565598A (en) * 1997-09-26 1999-04-23 Board Of Trustees Of The University Of Illinois, The Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
DE19847779C1 (de) * 1998-10-16 2000-02-03 Deutsches Krebsforsch p53-Bindungsregionen
US6696441B1 (en) * 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response

Also Published As

Publication number Publication date
DE69918072T2 (de) 2005-07-07
JP2002509732A (ja) 2002-04-02
US20010039013A1 (en) 2001-11-08
HK1038595A1 (en) 2002-03-22
CA2324444A1 (en) 1999-10-07
US6020135A (en) 2000-02-01
EP1064404A1 (de) 2001-01-03
AU3208599A (en) 1999-10-18
ATE269415T1 (de) 2004-07-15
WO1999050456A1 (en) 1999-10-07
EP1064404B1 (de) 2004-06-16
US6171798B1 (en) 2001-01-09

Similar Documents

Publication Publication Date Title
ATE269415T1 (de) P53-regulierte gene
Esposito et al. HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs
EP0804548A4 (de) Ptc gene und ihre verwendung
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
DE60039072D1 (de) Verfahren zum screenen von mehrfach transformierteon von fluoreszenzproteinen
DK1115840T3 (da) Afstamningsspecifikke celler og progenitorceller
ATE257177T1 (de) Adeno-assoziierte virale (avv) liposomen und damit zusammenhängende verfahren
AU4674079A (en) Compensating the magnetic field induced by the adjacent line in series of high intensity electrolysis cells
Wu et al. Chromatin remodeling protein HELLS is upregulated by inactivation of the RB-E2F pathway and is nonessential for osteosarcoma tumorigenesis
Borok et al. Differential regulation of rat aquaporin-5 promoter/enhancer activities in lung and salivary epithelial cells
ATE171212T1 (de) Corticotropin freisetzende rezeptoren des faktor 2
DE69934903D1 (de) Mitogene regulatoren
WO1998005797B1 (en) Prostate cancer drug screening
EP1450602A4 (de) Identifizierung und charakterisierung von genen
Nakamura et al. The combination of ubiquitous transcription factors AP‐1 and Sp1 directs keratinocyte‐specific and differentiation‐specific gene expression in vitro
DE69940022D1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
HU9503363D0 (en) Process for screening substances having a modulating effect on an interleukine-5-receptor-dependent cellular signal transmission path
Choder et al. RNA polymerase II allows unwinding and rewinding of the DNA and thus maintains a constant length of the transcription bubble.
BR9708256A (pt) Processo para identificar genes com expresão específica ao síto ou de síto preferido em células de marcacção específicas presentes em um ambiente de células diferente ou não daquele de sua origem e uso do mesmo
ATE297999T1 (de) Dna expression in transfizierten zellen und testverfahren in transfiziereen zellen
DE69432422D1 (de) Methoden zum aufspüren von anti-östrogenverbindungen
EP1814994A4 (de) Vorrichtung und system mit trockenen kontrollgen-verstummungszusammensetzungen
DE69715672D1 (de) Reporter-zellinie zum nachweis des cytomegalovirus und zur identifizierung von modulatoren der viralen genexpression
Kumar et al. Transfection mediated by DEAE-dextran
ATE328100T1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition